New treatment approach for prostate cancer using peptoid molecules
Official title: Peptoid conjugates targeting prostate cancer
Funded at New York University School of Medicine · NIH-10812127 · Data updated 2026-11-12
This study is exploring a new treatment for advanced prostate cancer using special molecules that can help fight cancer cells that don't respond to regular therapies, and it aims to find out how well these molecules work in boosting the body's immune response to improve patient outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $624,001 |
| NIH project number | 1R01CA276438-01A1 |
| Project ID | NIH-10812127 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer who have shown resistance to standard anti-androgen treatments.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone anti-androgen therapy may not benefit from this research.
What this research studies
This research investigates a novel method to combat prostate cancer by using specially designed molecules called multivalent peptoid conjugates (MPCs) that target the androgen receptor. These MPCs are engineered to resist breakdown in the body, allowing them to effectively inhibit the growth of prostate cancer cells that have become resistant to standard treatments like enzalutamide. The study will analyze how these peptoids interact with cancer cells and promote immune responses to enhance treatment effectiveness. Patients may benefit from a new therapeutic option that could improve outcomes for those with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with prostate cancer that is resistant to current therapies.
How similar studies have gone: Previous research has shown promise in using similar approaches to target cancer cells, indicating potential for success with this novel treatment strategy.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Garabedian, Michael J. — New York University School of Medicine
- Study coordinator: Garabedian, Michael J.
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.